Sooo, I just watched this.
Some takeaways for me.
Drug affect size has been calculated statistically based on the PAR005 and PAR008 trials, with a 'success' result estimated in Phase III to be 98-99%.
Yes, they calculated the average based on 005 and 008 and still got this result.
I can only imagine what it would be if they discarded the poorer 005 results.
Paul confirmed that active partnership meetings are on hold, pending the FDA tick for phase III
Once again, I heard no bad news.
Not advice, just my thoughts
LiveStream: Paradigm Biopharma (ASX:PAR) pursuing FDA review, page-10
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
26.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $92.81M | |||
| Open | High | Low | Value | Volume |
| 27.0¢ | 29.0¢ | 25.5¢ | $430.3K | 1.585M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5500 | 26.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.5¢ | 36162 | 3 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| PAR (ASX) Chart |